United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

Equities researchers at Stifel Canada issued their Q1 2025 earnings per share (EPS) estimates for shares of HLS Therapeutics ...

Reliv International Inc (RELV) is expected to report for 4Q. Rubicon Technology Inc (RBCN) is expected to report for 4Q. Ryvyl Inc (RVYL) is expected to report $-0.33 for 4Q. SouthGobi Resources Ltd ...

BofA analyst Tim Anderson raised the firm’s price target on Aardvark Therapeutics (AARD) to $26 from $22 and keeps a Buy rating on the shares ...

Cintas Corporation CTAS shares jumped over 8% on Wednesday after the company posted better-than-expected third-quarter ...

Maravai LifeSciences Holdings Inc (MRVI) is expected to report $-0.07 for 4Q. McCormick & Co Inc (MKC) is expected to report $0.64 for 1Q. Movado Group Inc (MOV) is expected to report $0.39 for 4Q.

The "Inhalable Biologics Market Size, Share & Trends Analysis Report by Biologics (Peptides & Proteins, Monoclonal Antibodies, RNAi-Based Therapeutics), Application (Diabetes, Cancer), Dosage Form, ...

Virios Therapeutics (VIRI) reported Q2 EPS of ($0.44), $0.07 better than the analyst estimate of ($0.51).

Silexion Therapeutics Corp (NASDAQ:SLXN), a biopharmaceutical company with a market capitalization of $10.77 million, announced on Monday that it has entered into an agreement to retire a convertible ...

Indeed, from their eight Shield outings at the venue since it earned first-class status in 2019, SA's sole victory there came against the Blues in the final round of the 2021-22 season.

BOSTON - Allarity Therapeutics, Inc. (NASDAQ: ALLR), a biopharmaceutical company in Phase 2 clinical stage trading at $1.02 per share, has announced the conclusion of its settlement with the U.S ...

SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted ...